Stockscreener 앱 받기
13.66
2.11%
-0.295
시장 영업 전:
13.64
-0.025
-0.18%
전일 마감가:
$13.96
열려 있는:
$13.37
하루 거래량:
1.43M
Relative Volume:
2.69
시가총액:
$692.44M
수익:
$80.33M
순이익/손실:
$29.34M
주가수익비율:
24.29
EPS:
0.5625
순현금흐름:
$243.48M
1주 성능:
-28.31%
1개월 성능:
-31.98%
6개월 성능:
-2.74%
1년 성능:
+50.16%
1일 변동 폭
$13.25
$14.10
1주일 범위
$13.08
$19.37
52주 변동 폭
$7.90
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
13.66 | 707.39M | 80.33M | 29.34M | 243.48M | 0.5625 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-12 | 개시 | B. Riley Securities | Buy |
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Market Moves: What’s the RSI of Theravance Biopharma Inc. stockLayoff News & Technical Buy Zone Confirmations - baoquankhu1.vn
B.Riley cuts Theravance Biopharma stock rating on trial failure - Investing.com Australia
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - TradingView
Share tumbles and jobs to go after Theravance failure - The Pharma Letter
B. Riley Financial Reiterates "Neutral" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
B. Riley Downgrades Theravance Biopharma to Neutral From Buy, Adjusts Price Target to $14 From $28 - marketscreener.com
Breaking Down Theravance Biopharma: 5 Analysts Share Their Views - Benzinga
This Vulcan Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
TBPH Analyst: HC Wainwright & Co. Lowers Price Target to $15 | T - GuruFocus
Theravance Biopharma (TBPH) Downgraded by B. Riley Securities to Neutral | TBPH Stock News - GuruFocus
Theravance to cut costs 60% after drug trial fails primary endpoint - Investing.com Canada
BTIG Maintains Buy on Theravance Biopharma, Inc. (TBPH) March 2026 - Meyka
Theravance Biopharma (TBPH): BTIG Lowers Price Target to $21.00 - GuruFocus
Theravance Biopharma Target of Unusually High Options Trading (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (TBPH) Phase 3 Study Misses Expectations - GuruFocus
Theravance Biopharma, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Resilience - Markets Mojo
Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down on Analyst Downgrade - MarketBeat
BTIG cuts Theravance Biopharma stock price target on trial miss By Investing.com - Investing.com Canada
BTIG Research Lowers Theravance Biopharma (NASDAQ:TBPH) Price Target to $21.00 - MarketBeat
Theravance slashes R&D as hypotension asset fails again - BioWorld MedTech
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review - Yahoo Finance UK
Theravance Biopharma stock tumbles after trial failure By Investing.com - Investing.com Canada
Theravance Biopharma stock tumbles after trial failure - Investing.com
Theravance considers possible sale after drug trial setback - marketscreener.com
Theravance Biopharma (TBPH) Shuts Down Ampreloxetine Program Pos - GuruFocus
Theravance Biopharma reports Phase 3 Cypress study did not meet primary endpoint; board accelerates strategic review and announces cost reduction actions - marketscreener.com
Theravance Biopharma to Restructure After Ampreloxetine Trial Fails to Meet Endpoint - marketscreener.com
Theravance Biopharma (TBPH) Shares Plummet After Disappointing S - GuruFocus
Theravance Biopharma (TBPH) to End Ampreloxetine Program Amid St - GuruFocus
Theravance Biopharma Inc. (TBPH) shares plunged 28% in pre-market trading after the company announced that its hypertension drug failed to meet the primary endpoint in a pivotal late-stage clinical trial. - Bitget
Theravance stock in focus after trial setback (TBPH:NASDAQ) - Seeking Alpha
Theravance Biopharma Restructures After Ampreloxetine Trial Failure - TipRanks
Phase 3 failure drives Theravance (NASDAQ: TBPH) restructuring and review - Stock Titan
Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions - TradingView
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PR Newswire
H.C. Wainwright raises Theravance Biopharma price target on trial progress - Investing.com
Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $27.00 - MarketBeat
TBPH Technical Analysis & Stock Price Forecast - Intellectia AI
Understanding the Setup: (TBPH) and Scalable Risk - Stock Traders Daily
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Evaluating A Potential 46.86% Upside - DirectorsTalk Interviews
Theravance Biopharma Experiences Valuation Adjustment Amid Strong Performance Metrics - Markets Mojo
TBPH Technical Analysis & ETF Price Forecast - Intellectia AI
TBPH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
Can Theravance Biopharma Inc reach resistance levels soonMarket Risk Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - TradingView
Theravance Biopharma (TBPH) SVP has 13,929 shares withheld for RSU taxes - Stock Titan
Hillsdale Investment Management Inc. Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Irenic Dumps Most Papa John's Shares - The Motley Fool
Theravance Biopharma Inc expected to post earnings of $1.13 a shareEarnings Preview - TradingView
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):